New GSM Treatments: Beyond Vaginal Lubricants

Beyond Lubricants: New Clinical Evidence Expands GSM Treatment Options

Genitourinary syndrome of menopause (GSM) affects nearly half of postmenopausal women, manifesting as vaginal dryness, pain, urinary urgency, and incontinence. For decades, treatment has focused on hormonal and non-hormonal lubricants. Fresh clinical research is now validating novel approaches that target tissue health and pelvic floor function, offering new hope for managing these persistent symptoms.

Light Therapy Shows Measurable Benefit for Urinary Incontinence

In a 2026 placebo-controlled, double-blind clinical trial, researchers from the Post-Graduation Program in Biophotonics Medicine at Universidade Nove de Julho in Brazil tested photobiomodulation (PBM) on 65 postmenopausal women with GSM. The treatment involved applying an 808 nm laser to eight points around the vaginal opening for 40 seconds each, once a week for four weeks. The placebo group underwent an identical procedure with the device off.

The results, measured by the standardized International Consultation on Incontinence Questionnaire, showed a significant reduction in urinary loss for the PBM group compared to placebo. Pereira and colleagues propose the mechanism is cellular: the near-infrared light is absorbed by the mitochondria in vaginal and pelvic floor cells, boosting cellular energy (ATP) production. This increased energy may stimulate tissue repair, reduce inflammation, and improve blood flow, leading to stronger, healthier connective tissue and muscle. The study also noted patient-reported improvements in vaginal dryness and burning, though changes in sexual function and pelvic pressure were not statistically significant.

A Framework for Individualized, Stepwise Care

A separate 2026 clinical perspective from Mayo Clinic specialists Cyriac and Sood frames these new options within a practical management strategy. They argue that treatment should be tailored and progressive. The first step involves non-hormonal therapies like moisturizers, lubricants, and pelvic floor physical therapy. For women who need more, or for whom these are insufficient, the next step is low-dose vaginal estrogen, which remains the most effective treatment for reversing atrophic tissue changes. For selected patients, other options like vaginal dehydroepiandrosterone (DHEA) or oral ospemifene may be considered.

This framework makes room for emerging technologies. The experts note that while data is still accumulating, therapies like PBM and electromagnetic pelvic floor stimulation represent promising non-hormonal, non-invasive tools. They work on a different pathway—bioenergetics and neuromuscular rehabilitation—rather than hormone replacement, which may appeal to women who cannot or prefer not to use estrogen.

Mechanisms Explain Why Single Solutions Often Fall Short

GSM is not a single problem but a cluster of symptoms stemming from estrogen deficiency’s impact on multiple tissue types. Estrogen receptors are abundant in the vagina, vulva, urethra, and pelvic floor muscles. When estrogen levels drop, these tissues become thin, dry, less elastic, and more easily inflamed. Blood flow decreases, and the vaginal microbiome can shift, sometimes increasing infection risk.

This complexity is why a lubricant may ease friction but won’t strengthen the urethra to prevent leakage, and why local estrogen may improve tissue quality but not correct a weak pelvic muscle. The Brazilian PBM study’s mixed results—helping dryness and incontinence but not sexual function—illustrate this perfectly. Sexual function involves psychological, relational, and hormonal factors beyond vaginal health, including testosterone levels, as explored in our article on testosterone and female libido. A holistic view of GSM acknowledges that treatment often requires a combination of approaches, potentially including systemic support like targeted probiotics for urogenital and overall health.

Integrating New Evidence into Personal Health Plans

For women navigating GSM, the current evidence supports a proactive and layered conversation with a healthcare provider. Start by detailing all symptoms—urinary, vaginal, and sexual—as each may point to a different solution. Non-hormonal moisturizers used regularly are a foundational first-line treatment for dryness.

If urinary incontinence is a primary concern, the new data on PBM adds another option to pelvic floor Kegel exercises and physical therapy. Ask a provider about the availability of clinically-supported PBM or electromagnetic stimulation devices. For persistent vaginal atrophy, low-dose vaginal estrogen is highly effective and has minimal systemic absorption. The Mayo Clinic perspective strongly recommends against ignoring symptoms or accepting them as an inevitable part of aging, as untreated GSM typically worsens over time.

Critically, the PBM study had a relatively short four-week follow-up. Longer-term studies are needed to determine how often maintenance treatments might be required and the full scope of benefits. Its non-significant finding on sexual function also reminds us that comprehensive care must address the whole person.

The landscape of GSM treatment is moving beyond simple lubrication. Robust clinical trials are now providing evidence for therapies that actively improve tissue repair and muscle function. By understanding the mechanisms behind both established and emerging options, women and their clinicians can develop more effective, personalized strategies to restore comfort and quality of life.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42060269/
https://pubmed.ncbi.nlm.nih.gov/41892504/